Correction to: As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?

Christian Domingo^{1,2} · Jordi Rello³ · Ana Sogo^{1,2}

Published online: 29 October 2019
© Springer Nature Switzerland AG 2019

Correction to: Drugs (2019)
<https://doi.org/10.1007/s40265-019-01202-0>

Abstract, fourth to last sentence, which currently reads:

Despite this poor evidence, and ignoring the clinical histological benefits of chronic inhaled corticosteroids (especially when administered promptly), GINA 2019 recently recommended daily low dose ICS or ICS–ICS as needed as a first option for step 2 patients.

Should read:

Despite this poor evidence, and ignoring the clinical histological benefits of chronic inhaled corticosteroids (especially when administered promptly), GINA 2019 recently recommended daily low dose ICS or ICS-LABA as needed as a first option for step 2 patients.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40265-019-01202-0>.

✉ Christian Domingo
cdomingo@tauli.cat

¹ Servei de Pneumologia, Corporació Sanitària Parc Taulí, Parc Taulí s/n, 08208 Sabadell (Barcelona), Spain

² Departament de Medicina, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

³ CIBERES, Instituto Salud Carlos III and Vall d'Hebron Institute of Research, Barcelona, Spain